Oxbryta Prior Authorization Criteria Updates Scheduled for April 5

Published on
February 16, 2022

On April 5, 2022, HHSC will revise the prior authorization criteria in the Sickle Cell Disease Agents clinical prior authorization (PDF) for Oxbryta (voxelotor) to ensure alignment with the U. S. Food and Drug Administration-approved indications and package inserts.

The criteria update includes the FDA’s recent age expansion to 4 years and older, and the removal of criteria step 6 relating to the drug interaction with CYP3A4 inhibitors or fluconazole. The updated criteria guide document also includes pediatric dosing information tables.

This clinical prior authorization is optional for managed care. The Clinical Prior Authorization Assistance Chart indicates which prior authorization each MCO uses. The chart is updated quarterly. Providers can also refer to the MCO Resources for links to each MCO's list of clinical prior authorizations.